Cobas amplicor cobas taqman

Manufactured by Roche

Sourced in Switzerland

The COBAS Amplicor-COBAS TaqMan is a laboratory instrument designed for automated nucleic acid amplification and detection. It utilizes real-time PCR technology to perform qualitative and quantitative analysis of various target sequences. The core function of this product is to enable efficient and accurate molecular diagnostic testing in a laboratory setting.

Automatically generated - may contain errors

Lab products found in correlation

Spelling variants of this product

Cobas TaqMan (73 citations) Cobas Amplicor (64 citations) COBAS Amplicor V2.0/Taqman-48 system (2 citations) Roche Amplicor monitor standard assay (COBAS AmpliPrep/COBAS TaqMan HIV Test; (2 citations)

3 protocols using cobas amplicor cobas taqman

Quantification of Serum HBV-DNA

Check if the same lab product or an alternative is used in the 5 most similar protocols

Serum HBV-DNA was quantified by a real-time PCR system (COBAS Amplicor-COBAS TaqMan, Roche, Basel, Switzerland; lower limit of quantitation [LLoQ]:20 IU/m). The values of HBV-DNA were log transformed and expressed in log10 IU/mL.

Piermatteo L., Alkhatib M., D’Anna S., Malagnino V., Bertoli A., Andreassi E., Basile E., Iuvara A., De Cristofaro M., Cappiello G., Cerva C., Minichini C., Pisaturo M., Starace M., Coppola N., Fontana C., Grelli S., Ceccherini-Silberstein F., Andreoni M., Gill U.S., Kennedy P.T., Sarmati L., Salpini R, & Svicher V. (2021). HBeAg Levels Vary across the Different Stages of HBV Infection According to the Extent of Immunological Pressure and Are Associated with Therapeutic Outcome in the Setting of Immunosuppression-Driven HBV Reactivation. Biomedicines, 9(10), 1352.

+ Open protocol

+ Expand

Quantitative HBsAg and HBV-DNA Detection

Check if the same lab product or an alternative is used in the 5 most similar protocols

Serum HBsAg was tested by using the commercially available quantitative HBsAg detection system (Abbott Architect, lower limit of detection: 50 mIU/mL, routinely used at Tor Vergata Policlinic for diagnostic purposes) (Abbott Diagnostics, Abbott Park, IL, USA). Similarly, the qualitative detection of HBeAg, anti-HBe, and anti-HBs serological markers was performed by using the Abbott Architect instrument (Abbott Diagnostics, Abbott Park, IL, USA).
Serum HBV-DNA was quantified by a fully automated Real-Time PCR system (COBAS Amplicor-COBAS TaqMan, Roche, Basel, Switzerland), characterized by a lower limit of quantitation (LLoQ) of 20 IU/mL.

Salpini R., Malagnino V., Piermatteo L., Mulas T., Alkhatib M., Scutari R., Teti E., Cerva C., Yu La Rosa K., Brugneti M., Bertoli A., Rossi B., Holzmayer V., Gersch J., Kuhns M., Cloherty G., Ceccherini-Silberstein F., Perno C.F., Iannetta M., Andreoni M., Sarmati L, & Svicher V. (2020). Cryptic HBV Replicative Activity Is Frequently Revealed in Anti-HBc-Positive/HBsAg-Negative Patients with HIV Infection by Highly Sensitive Molecular Assays, and Can Be Predicted by Integrating Classical and Novel Serological HBV Markers. Microorganisms, 8(11), 1819.

+ Open protocol

+ Expand

Quantitative HBsAg and HBV DNA Testing

Check if the same lab product or an alternative is used in the 5 most similar protocols

HBsAg was tested by the commercially available quantitative HBsAg detection system (Abbott Architect, lower limit of detection (LLoD): 50 mIU/mL (routinely used for diagnostic purposes at University Hospital Tor Vergata) (Abbott Diagnostics, Abbott Park, IL, USA). Similarly, the qualitative detection of anti-HBc and anti-HBs titres was assessed by the Abbott Architect instrument (Abbott Diagnostics, Abbott Park, IL, USA). Serum HBV DNA was quantified by a real-time PCR system (COBAS Amplicor-COBAS TaqMan, Roche, Basel, Switzerland; lower limit of quantitation (LLoQ): 20 IU/m).

Cerva C., Salpini R., Alkhatib M., Malagnino V., Piermatteo L., Battisti A., Bertoli A., Gersch J., Holzmayer V., Kuhns M., Cloherty G., Ferrari L., Laura C., Teti E., Cantonetti M., Arcese W., Ceccherini-Silberstein F., Perno C.F., Andreoni M., Svicher V, & Sarmati L. (2022). Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients. Biomedicines, 10(2), 443.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!